Pyxis Oncology launches registered offering of stock, pre-funded warrants and common warrants
PYXS•Pyxis Oncology launched a registered offering of common stock or pre-funded warrants, each paired with a common warrant; proceeds are earmarked for MICVO development and working capital.
1. Offering details
The common warrants become exercisable only after stockholder approval of a charter amendment increasing authorized common shares. They expire on the earlier of five years from the amendment’s effective date or 30 days after MICVO overall survival data are disclosed. Leerink Partners, Guggenheim Securities and Wells Fargo Securities are joint bookrunning managers, and deal terms remain subject to market conditions.
